a privately-held life sciences company that has developed a
droplet-based DNA sequencing technology, today announced that it was
acquired by Bio-Rad
Laboratories, Inc. With this acquisition, Bio-Rad will expand its
Digital Biology Center and establish a research and development site in
has developed a DNA sequencing solution that integrates the entire
sample preparation workflow on a chip, from sample capture, PCR, and
sequencing, to informatics. This capability offers a "Sample In, Answer
Out" DNA sequencing solution whereby a technician or researcher simply
loads genomic DNA into the cartridge and presses a utton to start the
run with results delivered within hours, versus days.
leading positions in the clinical IVD market as well as the Droplet
Digital™ PCR space make Bio-Rad the ideal acquisition partner for us,"
said John Boyce, President, CEO, and Founder of GnuBIO.
"Bio-Rad's reputation as well as its presence in both the clinical and
research markets will be essential elements to the success of the GnuBIO
platform. We are very excited to join the Bio-Rad family," Boyce added.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) designs, manufactures,
and distributes a broad range of innovative products and solutions for
the life science research and clinical diagnostic markets. The company
is renowned for its commitment to quality and customer service among
university and research institutions, hospitals, public health and
commercial laboratories, as well as the biotechnology, pharmaceutical,
and food safety industries. Founded in 1952, Bio-Rad is based in
Hercules, California, and serves more than 100,000 research and
healthcare industry customers through its global network of operations.
The company employs approximately 7,750 people worldwide and had
revenues exceeding $2.1 billion in 2013. For more information, visit our
website at www.bio-rad.com.
Based in Cambridge, Massachusetts, GnuBIO
is developing a droplet-based DNA sequencing platform. The innovative
system is the first fully-integrated DNA sequencing platform that
utilizes microfluidic and emulsion technology to perform complex,
multiplexed reactions in droplets. This will allow both researchers and
clinicians in the future to perform complete DNA sequencing workflows in
a few hours instead of days.
[ Back To NFVZone's Homepage ]